Search Results for "ATTRv"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program

Musculoskeletal Manifestations Associated with ATTR Amyloidosis

This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.

DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis

Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank

The Journey to Diagnosis of Wild-Type ATTR Amyloidosis: A Path with Multisystem Involvement

Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

ATTR Amyloidosis Disease State Handout

This handout provides an overview of ATTR amyloidosis manifestations and the diagnostic tools that can be used to assess their presentation.

History of Polyneuropathy and Musculoskeletal Manifestations in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy in APOLLO-B

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement

The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.